#热词#2021年度生命科学十大进展出炉 本年度入选成果包括8个知识创新类和2个技术创新类项目成果。Chinese scientists have developed an artificial method of synthesizing starch from carbon dioxide, the first of its kind globally. 其中，“从二氧化碳到淀粉的人工合成”研究在国际上首次实现了二氧化碳到淀粉的人工全合成。 https://t.cn/A6JtVHqD
#南大新闻# 【南京大学现代工学院在原位构筑锂金属人工SEI膜研究上取得重要进展】近日，南京大学现代工学院提出了在锂金属上利用多环芳烃（PAHs）原位构建π-π堆积的有机-无机杂化层作为人工固态电解质界面（SEI）膜策略。
以上成果以In Situ Formation of Polycyclic Aromatic Hydrocarbons as an Artificial Hybrid Layer for Lithium Metal Anodes为题发表在国际期刊Nano Letter。论文的第一作者为南京大学现代工程与应用科学学院2020级博士生昌绍忠，通讯作者为南京大学现代工程与应用科学学院的张会刚、李爱东教授和美国阿贡国家实验室陆俊、Khalil Amine教授。#南大科研动态#
以上成果以In Situ Formation of Polycyclic Aromatic Hydrocarbons as an Artificial Hybrid Layer for Lithium Metal Anodes为题发表在国际期刊Nano Letter。论文的第一作者为南京大学现代工程与应用科学学院2020级博士生昌绍忠，通讯作者为南京大学现代工程与应用科学学院的张会刚、李爱东教授和美国阿贡国家实验室陆俊、Khalil Amine教授。#南大科研动态#
#信我U健康# 基于mRNA技术研发的、能够预防艾滋病的疫苗，在早期动物实验中获得了成功，该研究成果已公开发表于《自然医学分册》......。
“An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus. Rhesus macaques receiving a priming vaccine followed by multiple booster inoculations had a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus (SHIV) compared to unvaccinated animals. The research was led by Paolo Lusso, M.D., Ph.D., of NIAID’s Laboratory of Immunoregulation, in collaboration with other NIAID scientists, investigators from Moderna, Inc. and colleagues at other institutions.”
“An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus. Rhesus macaques receiving a priming vaccine followed by multiple booster inoculations had a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus (SHIV) compared to unvaccinated animals. The research was led by Paolo Lusso, M.D., Ph.D., of NIAID’s Laboratory of Immunoregulation, in collaboration with other NIAID scientists, investigators from Moderna, Inc. and colleagues at other institutions.”
✋热门推荐